{"id":700,"date":"2023-05-09T20:30:10","date_gmt":"2023-05-09T20:30:10","guid":{"rendered":"http:\/\/eurosoi.org\/?p=700"},"modified":"2023-05-09T20:30:10","modified_gmt":"2023-05-09T20:30:10","slug":"2012","status":"publish","type":"post","link":"https:\/\/eurosoi.org\/?p=700","title":{"rendered":"\ufeff2012)"},"content":{"rendered":"<p>\ufeff2012). develop similar tests that could benefit diagnostic strategies for other infections. Key points ? (Mtb) transmission is disrupted, global TB elimination targets are unlikely to be attained (Lonnroth and Raviglione 2016; Uplekar et al. 2015; WHO 2018b). Accordingly, the US Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Eliminations strategic plan includes accelerating <a href=\"https:\/\/www.adooq.com\/retigabine-ezogabine.html\">Retigabine (Ezogabine)<\/a> the decline in TB through targeted testing and treatment of latent TB infection (LTBI) (CDC 2020). At present, TB diagnosis uses indirect methods such as chest X-rays a well as direct detection methods that include 4-week culture of Mtb from sputum samples. Nucleic acid amplification tests (NAAT; e.g., GeneXpert) have sped up the provision of more sensitive and specific results (Boehme et al. 2011; Nicol et al. 2011), and IFN- release assays (IGRA) that assess cytokine production following incubation of unfractionated blood with Mtb antigens have also been developed (Arenas Miras Mdel et al. 2013; Arias Guillen 2011; Rangaka et al. 2012) (Fig. ?(Fig.1).1). Clinicians have great familiarity with skin testing, which requires no laboratory-based technology, and TST has been the standard TB screening\/surveillance tool for decades (Bass Jr 2003; Snider Jr 1982). Open in a separate window Fig. 1 Logistics of conducting ex vivo T cellCbased testing and in vivo skin testing TST uses purified protein derivative (PPD; tuberculin) to detect T cell responses against Mtb. PPD was produced by first steaming cultures of then repeatedly precipitating with ammonium sulfate to purify the proteins while reducing polysaccharide, nucleic acid, and lipid content. In 1944, a large lot of PPD-Standard (PPD-S) was made that comprised approximately 92.9% protein, 5.9% polysaccharide, and 1.2% nucleic acid. Eight years later, the World Health Organization (WHO) adopted the PPD-S as the international standard (Guld et al. 1958; Seibert and Glen 1941). Retigabine (Ezogabine) Retigabine (Ezogabine) The Food and Drug Administration (FDA) required that all lots of PPD be Retigabine (Ezogabine) qualified and show a potency equivalent to PPD-S. A standard preparation derived from one solitary batch, Master Batch Connaught Tuberculin (CT68), was then adopted to eliminate batch-to-batch variation Retigabine (Ezogabine) (Landi and Held 1980; Sbarbaro 1978). There are now, however, many varieties of PPD in use: PPD-S in the USA; PPD RT23 is the most widely used PPD product outside of North America; PPD RT23 Mexico is used in Latin America; PPD-s is used in Japan; and PPD-L is used in Russia (Comstock et al. 1964; Kimura et al. 2005; Rangel-Frausto et al. 2001; Starshinova et al. 2018; Yang et al. 2012). PPD-S2, the current US standard that was developed to address the eventual depletion of PPD-S, is used in the commercially available Aplisol? and Tubersol? (Jensen et al. 2005; Villarino et al. 2000). Although results with Aplisol? and Tubersol? were comparable to those of the original PPD-S, shifting the use between Tubersol? and Aplisol? has resulted in aberrations that are unexplained (Gillenwater et al. 2006; Mehta et al. 2009; Villarino et al. 1999). Both Aplisol and Tubersol have experienced regular shortages (CDC 2013b) and routine health department activities had been threatened or already curtailed in 56% US jurisdictions due to reported shortages of PPD TST antigen solutions (10 Tubersol only, four Aplisol only, and 15 both) (CDC 2013a). In June 2019, the US Centers for Disease Control (CDC) announced an anticipated 3C10-month shortage of Aplisol (2019). This limitation could potentially be overcome through the use of defined, species-specific proteins. Mass spectrometry and molecular analyses identified over one hundred proteins from four different PPD, and revealed that roughly 60% of the total protein content is contributed by heat shock proteins GroEl, GroEs, DnaK, and HspX (Borsuk et al. 2009; Cho et al. 2012). These heat shock proteins are conserved among most mycobacterial species, and it is believed that this broad mixture limits the ability of PPD-based TST to distinguish infection from either <a href=\"http:\/\/www.baylor.edu\/~PR\/Beall\/Song.html\">LIF<\/a> exposure to non-tuberculous mycobacteria or vaccination with BCG (Farhat et al. 2006; Huebner et al. 1993). Many TB experts have favored.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeff2012). develop similar tests that could benefit diagnostic strategies for other infections. Key points ? (Mtb) transmission is disrupted, global TB elimination targets are unlikely to be attained (Lonnroth and Raviglione 2016; Uplekar et al. 2015; WHO 2018b). Accordingly, the US Centers for Disease Control and Prevention (CDC) Division of <a href=\"https:\/\/eurosoi.org\/?p=700\" class=\"btn btn-link continue-link\">Continue Reading<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[60],"tags":[],"class_list":["post-700","post","type-post","status-publish","format-standard","hentry","category-kinases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeff2012) - JAK2 inhibitor against human prostate cancer cells<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/eurosoi.org\/?p=700\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeff2012) - JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"og:description\" content=\"\ufeff2012). develop similar tests that could benefit diagnostic strategies for other infections. Key points ? (Mtb) transmission is disrupted, global TB elimination targets are unlikely to be attained (Lonnroth and Raviglione 2016; Uplekar et al. 2015; WHO 2018b). Accordingly, the US Centers for Disease Control and Prevention (CDC) Division of Continue Reading\" \/>\n<meta property=\"og:url\" content=\"https:\/\/eurosoi.org\/?p=700\" \/>\n<meta property=\"og:site_name\" content=\"JAK2 inhibitor against human prostate cancer cells\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-09T20:30:10+00:00\" \/>\n<meta name=\"author\" content=\"info\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"info\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700\"},\"author\":{\"name\":\"info\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"headline\":\"\ufeff2012)\",\"datePublished\":\"2023-05-09T20:30:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700\"},\"wordCount\":620,\"articleSection\":[\"Kinases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/?p=700\",\"name\":\"\ufeff2012) - JAK2 inhibitor against human prostate cancer cells\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\"},\"datePublished\":\"2023-05-09T20:30:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/eurosoi.org\\\/?p=700\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/?p=700#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/eurosoi.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeff2012)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#website\",\"url\":\"https:\\\/\\\/eurosoi.org\\\/\",\"name\":\"JAK2 inhibitor against human prostate cancer cells\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/eurosoi.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/eurosoi.org\\\/#\\\/schema\\\/person\\\/ba68ae543ef2903c0b995cd8992cedfd\",\"name\":\"info\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g\",\"caption\":\"info\"},\"sameAs\":[\"http:\\\/\\\/eurosoi.org\"],\"url\":\"https:\\\/\\\/eurosoi.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeff2012) - JAK2 inhibitor against human prostate cancer cells","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/eurosoi.org\/?p=700","og_locale":"en_US","og_type":"article","og_title":"\ufeff2012) - JAK2 inhibitor against human prostate cancer cells","og_description":"\ufeff2012). develop similar tests that could benefit diagnostic strategies for other infections. Key points ? (Mtb) transmission is disrupted, global TB elimination targets are unlikely to be attained (Lonnroth and Raviglione 2016; Uplekar et al. 2015; WHO 2018b). Accordingly, the US Centers for Disease Control and Prevention (CDC) Division of Continue Reading","og_url":"https:\/\/eurosoi.org\/?p=700","og_site_name":"JAK2 inhibitor against human prostate cancer cells","article_published_time":"2023-05-09T20:30:10+00:00","author":"info","twitter_card":"summary_large_image","twitter_misc":{"Written by":"info","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/eurosoi.org\/?p=700#article","isPartOf":{"@id":"https:\/\/eurosoi.org\/?p=700"},"author":{"name":"info","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"headline":"\ufeff2012)","datePublished":"2023-05-09T20:30:10+00:00","mainEntityOfPage":{"@id":"https:\/\/eurosoi.org\/?p=700"},"wordCount":620,"articleSection":["Kinases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/eurosoi.org\/?p=700","url":"https:\/\/eurosoi.org\/?p=700","name":"\ufeff2012) - JAK2 inhibitor against human prostate cancer cells","isPartOf":{"@id":"https:\/\/eurosoi.org\/#website"},"datePublished":"2023-05-09T20:30:10+00:00","author":{"@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd"},"breadcrumb":{"@id":"https:\/\/eurosoi.org\/?p=700#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/eurosoi.org\/?p=700"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/eurosoi.org\/?p=700#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/eurosoi.org\/"},{"@type":"ListItem","position":2,"name":"\ufeff2012)"}]},{"@type":"WebSite","@id":"https:\/\/eurosoi.org\/#website","url":"https:\/\/eurosoi.org\/","name":"JAK2 inhibitor against human prostate cancer cells","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/eurosoi.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/eurosoi.org\/#\/schema\/person\/ba68ae543ef2903c0b995cd8992cedfd","name":"info","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/deee51ad824afccf8f584928d162e0fea08029f81b2d40a83307df75388ac916?s=96&d=mm&r=g","caption":"info"},"sameAs":["http:\/\/eurosoi.org"],"url":"https:\/\/eurosoi.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=700"}],"version-history":[{"count":1,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/700\/revisions"}],"predecessor-version":[{"id":701,"href":"https:\/\/eurosoi.org\/index.php?rest_route=\/wp\/v2\/posts\/700\/revisions\/701"}],"wp:attachment":[{"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurosoi.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}